Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

T-cell depletion of bone marrow for allogeneic transplantation is known to increase the risks of Epstein-Barr virus-driven lymphoproliferative disorders that may result in fatal lymphoma, especially with transplants from unrelated or mismatched donors. Over the past 15 years, we have monitored the outcome of 2,582 transplants using CAMPATH-1 (CD52) antibodies to deplete lymphocytes from donor and/or recipient to prevent graft-versus-host disease or rejection. Unlike many other methods of T-cell depletion, CAMPATH-1 antibodies also deplete B lymphocytes. The actuarial risk of lymphoproliferative disease using CAMPATH-1 for depletion of donor lymphocytes was up to 1.3%, hardly different from reported figures for conventional nondepleted transplants. In contrast, the risk in a small group of patients transplanted from unrelated donors using E-rosette depletion was as high as 29%, comparable to other reports of specific T-cell depletion. We conclude that the additional depletion of B cells is beneficial, possibly because it reduces either the virus load or the virus target until the time when T cells begin to regenerate.


Journal article



Publication Date





3079 - 3083


Adolescent, Adult, Antibodies, Antigens, CD, Antigens, Neoplasm, Bone Marrow Transplantation, CD52 Antigen, Child, Child, Preschool, Female, Glycoproteins, Herpesvirus 4, Human, Humans, Immunosuppression, Infant, Lymphocyte Depletion, Lymphoproliferative Disorders, Male, Middle Aged, T-Lymphocytes